Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. A syndicate of investors led by BVF Partners has come together to help Nimbus find out if its prospect lives up to that promise. Equipped with cash from new and existing investors including RA Capital Management, Atlas Venture, Access Biotechnology and Commodore Capital, Nimbus plans to start multiple phase 2 studies in 2021 and 2022.